Viking Therapeutics Secures $706M Cash, Vanquish Trials Exceed 4,500 Enrollments
Viking Therapeutics ended 2025 with $706 million in cash to fund Phase 3 VANQUISH trials for its subcutaneous VK2735, with VANQUISH-1 surpassing 4,500 patient enrollments and VANQUISH-2 nearing full enrollment. This robust cash position and accelerated enrollment pace set the stage for near-term clinical readouts and potential value catalysts.
1. Financial Results and Cash Position
Viking Therapeutics reported fourth quarter and full-year 2025 results, ending with $706 million in cash and investments to fund ongoing research and development initiatives.
2. VANQUISH Trial Enrollment Progress
Enrollment in its Phase 3 VANQUISH program for subcutaneous VK2735 advanced ahead of schedule, with VANQUISH-1 exceeding 4,500 patients and VANQUISH-2 approaching full enrollment.
3. Future Catalysts and Outlook
The strong cash runway and trial momentum positions the company for potential near-term catalysts from top-line data releases and regulatory milestones in its obesity portfolio.